Click for best price
NextGeneration Gynecological Cancer Diagnostics Market Size, Share 2023
This report contains market size and forecasts of Next-Generation Gynecological Cancer Diagnostics in Global, including the following market information:
Global Next-Generation Gynecological Cancer Diagnostics Market Revenue, 2018-2023, 2023-2030, ($ millions)
Global top five companies in 2022 (%)
The global Next-Generation Gynecological Cancer Diagnostics market was valued at million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period 2023-2030.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million by 2030.
Ovarian Cancer Diagnosis Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Next-Generation Gynecological Cancer Diagnostics include Quest Diagnostics Incorporated, Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Invitae Corporation, Konica Minolta, Inc., BGI Genomics, CENTOGENE N.V., Fulgent Genetics, Inc. and Illumina, Inc., etc. In 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Next-Generation Gynecological Cancer Diagnostics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Next-Generation Gynecological Cancer Diagnostics Market, by Type, 2018-2023, 2023-2030 ($ millions)
Global Next-Generation Gynecological Cancer Diagnostics Market Segment Percentages, by Type, 2022 (%)
Ovarian Cancer Diagnosis
Cervical Cancer Diagnosis
Uterine Cancer Diagnosis
Global Next-Generation Gynecological Cancer Diagnostics Market, by Application, 2018-2023, 2023-2030 ($ millions)
Global Next-Generation Gynecological Cancer Diagnostics Market Segment Percentages, by Application, 2022 (%)
Hospitals
Clinics
Others
Global Next-Generation Gynecological Cancer Diagnostics Market, By Region and Country, 2018-2023, 2023-2030 ($ Millions)
Global Next-Generation Gynecological Cancer Diagnostics Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Next-Generation Gynecological Cancer Diagnostics revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Next-Generation Gynecological Cancer Diagnostics revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Quest Diagnostics Incorporated
Thermo Fisher Scientific Inc.
Agilent Technologies, Inc.
Invitae Corporation
Konica Minolta, Inc.
BGI Genomics
CENTOGENE N.V.
Fulgent Genetics, Inc.
Illumina, Inc.
F. Hoffmann-La Roche Ltd
Laboratory Corporation of America Holdings
ARUP Laboratories
Myriad Genetics, Inc.
OPKO Health, Inc.
QIAGEN N.V.
| Report Attributes |
Report Details |
| Report Title |
Next-Generation Gynecological Cancer Diagnostics Market, Global Outlook and Forecast 2023-2030 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
107 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Next-Generation Gynecological Cancer Diagnostics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Next-Generation Gynecological Cancer Diagnostics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Next-Generation Gynecological Cancer Diagnostics Overall Market Size
2.1 Global Next-Generation Gynecological Cancer Diagnostics Market Size: 2022 VS 2030
2.2 Global Next-Generation Gynecological Cancer Diagnostics Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Next-Generation Gynecological Cancer Diagnostics Players in Global Market
3.2 Top Global Next-Generation Gynecological Cancer Diagnostics Companies Ranked by Revenue
3.3 Global Next-Generation Gynecological Cancer Diagnostics Revenue by Companies
3.4 Top 3 and Top 5 Next-Generation Gynecological Cancer Diagnostics Companies in Global Market, by Revenue in 2022
3.5 Global Companies Next-Generation Gynecological Cancer Diagnostics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Next-Generation Gynecological Cancer Diagnostics Players in Global Market
3.6.1 List of Global Tier 1 Next-Generation Gynecological Cancer Diagnostics Companies
3.6.2 List of Global Tier 2 and Tier 3 Next-Generation Gynecological Cancer Diagnostics Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Next-Generation Gynecological Cancer Diagnostics Market Size Markets, 2022 & 2030
4.1.2 Ovarian Cancer Diagnosis
4.1.3 Cervical Cancer Diagnosis
4.1.4 Uterine Cancer Diagnosis
4.2 By Type - Global Next-Generation Gynecological Cancer Diagnostics Revenue & Forecasts
4.2.1 By Type - Global Next-Generation Gynecological Cancer Diagnostics Revenue, 2018-2023
4.2.2 By Type - Global Next-Generation Gynecological Cancer Diagnostics Revenue, 2023-2030
4.2.3 By Type - Global Next-Generation Gynecological Cancer Diagnostics Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Next-Generation Gynecological Cancer Diagnostics Market Size, 2022 & 2030
5.1.2 Hospitals
5.1.3 Clinics
5.1.4 Others
5.2 By Application - Global Next-Generation Gynecological Cancer Diagnostics Revenue & Forecasts
5.2.1 By Application - Global Next-Generation Gynecological Cancer Diagnostics Revenue, 2018-2023
5.2.2 By Application - Global Next-Generation Gynecological Cancer Diagnostics Revenue, 2023-2030
5.2.3 By Application - Global Next-Generation Gynecological Cancer Diagnostics Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Next-Generation Gynecological Cancer Diagnostics Market Size, 2022 & 2030
6.2 By Region - Global Next-Generation Gynecological Cancer Diagnostics Revenue & Forecasts
6.2.1 By Region - Global Next-Generation Gynecological Cancer Diagnostics Revenue, 2018-2023
6.2.2 By Region - Global Next-Generation Gynecological Cancer Diagnostics Revenue, 2023-2030
6.2.3 By Region - Global Next-Generation Gynecological Cancer Diagnostics Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Next-Generation Gynecological Cancer Diagnostics Revenue, 2018-2030
6.3.2 US Next-Generation Gynecological Cancer Diagnostics Market Size, 2018-2030
6.3.3 Canada Next-Generation Gynecological Cancer Diagnostics Market Size, 2018-2030
6.3.4 Mexico Next-Generation Gynecological Cancer Diagnostics Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Next-Generation Gynecological Cancer Diagnostics Revenue, 2018-2030
6.4.2 Germany Next-Generation Gynecological Cancer Diagnostics Market Size, 2018-2030
6.4.3 France Next-Generation Gynecological Cancer Diagnostics Market Size, 2018-2030
6.4.4 U.K. Next-Generation Gynecological Cancer Diagnostics Market Size, 2018-2030
6.4.5 Italy Next-Generation Gynecological Cancer Diagnostics Market Size, 2018-2030
6.4.6 Russia Next-Generation Gynecological Cancer Diagnostics Market Size, 2018-2030
6.4.7 Nordic Countries Next-Generation Gynecological Cancer Diagnostics Market Size, 2018-2030
6.4.8 Benelux Next-Generation Gynecological Cancer Diagnostics Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Next-Generation Gynecological Cancer Diagnostics Revenue, 2018-2030
6.5.2 China Next-Generation Gynecological Cancer Diagnostics Market Size, 2018-2030
6.5.3 Japan Next-Generation Gynecological Cancer Diagnostics Market Size, 2018-2030
6.5.4 South Korea Next-Generation Gynecological Cancer Diagnostics Market Size, 2018-2030
6.5.5 Southeast Asia Next-Generation Gynecological Cancer Diagnostics Market Size, 2018-2030
6.5.6 India Next-Generation Gynecological Cancer Diagnostics Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Next-Generation Gynecological Cancer Diagnostics Revenue, 2018-2030
6.6.2 Brazil Next-Generation Gynecological Cancer Diagnostics Market Size, 2018-2030
6.6.3 Argentina Next-Generation Gynecological Cancer Diagnostics Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Revenue, 2018-2030
6.7.2 Turkey Next-Generation Gynecological Cancer Diagnostics Market Size, 2018-2030
6.7.3 Israel Next-Generation Gynecological Cancer Diagnostics Market Size, 2018-2030
6.7.4 Saudi Arabia Next-Generation Gynecological Cancer Diagnostics Market Size, 2018-2030
6.7.5 UAE Next-Generation Gynecological Cancer Diagnostics Market Size, 2018-2030
7 Players Profiles
7.1 Quest Diagnostics Incorporated
7.1.1 Quest Diagnostics Incorporated Corporate Summary
7.1.2 Quest Diagnostics Incorporated Business Overview
7.1.3 Quest Diagnostics Incorporated Next-Generation Gynecological Cancer Diagnostics Major Product Offerings
7.1.4 Quest Diagnostics Incorporated Next-Generation Gynecological Cancer Diagnostics Revenue in Global Market (2018-2023)
7.1.5 Quest Diagnostics Incorporated Key News
7.2 Thermo Fisher Scientific Inc.
7.2.1 Thermo Fisher Scientific Inc. Corporate Summary
7.2.2 Thermo Fisher Scientific Inc. Business Overview
7.2.3 Thermo Fisher Scientific Inc. Next-Generation Gynecological Cancer Diagnostics Major Product Offerings
7.2.4 Thermo Fisher Scientific Inc. Next-Generation Gynecological Cancer Diagnostics Revenue in Global Market (2018-2023)
7.2.5 Thermo Fisher Scientific Inc. Key News
7.3 Agilent Technologies, Inc.
7.3.1 Agilent Technologies, Inc. Corporate Summary
7.3.2 Agilent Technologies, Inc. Business Overview
7.3.3 Agilent Technologies, Inc. Next-Generation Gynecological Cancer Diagnostics Major Product Offerings
7.3.4 Agilent Technologies, Inc. Next-Generation Gynecological Cancer Diagnostics Revenue in Global Market (2018-2023)
7.3.5 Agilent Technologies, Inc. Key News
7.4 Invitae Corporation
7.4.1 Invitae Corporation Corporate Summary
7.4.2 Invitae Corporation Business Overview
7.4.3 Invitae Corporation Next-Generation Gynecological Cancer Diagnostics Major Product Offerings
7.4.4 Invitae Corporation Next-Generation Gynecological Cancer Diagnostics Revenue in Global Market (2018-2023)
7.4.5 Invitae Corporation Key News
7.5 Konica Minolta, Inc.
7.5.1 Konica Minolta, Inc. Corporate Summary
7.5.2 Konica Minolta, Inc. Business Overview
7.5.3 Konica Minolta, Inc. Next-Generation Gynecological Cancer Diagnostics Major Product Offerings
7.5.4 Konica Minolta, Inc. Next-Generation Gynecological Cancer Diagnostics Revenue in Global Market (2018-2023)
7.5.5 Konica Minolta, Inc. Key News
7.6 BGI Genomics
7.6.1 BGI Genomics Corporate Summary
7.6.2 BGI Genomics Business Overview
7.6.3 BGI Genomics Next-Generation Gynecological Cancer Diagnostics Major Product Offerings
7.6.4 BGI Genomics Next-Generation Gynecological Cancer Diagnostics Revenue in Global Market (2018-2023)
7.6.5 BGI Genomics Key News
7.7 CENTOGENE N.V.
7.7.1 CENTOGENE N.V. Corporate Summary
7.7.2 CENTOGENE N.V. Business Overview
7.7.3 CENTOGENE N.V. Next-Generation Gynecological Cancer Diagnostics Major Product Offerings
7.7.4 CENTOGENE N.V. Next-Generation Gynecological Cancer Diagnostics Revenue in Global Market (2018-2023)
7.7.5 CENTOGENE N.V. Key News
7.8 Fulgent Genetics, Inc.
7.8.1 Fulgent Genetics, Inc. Corporate Summary
7.8.2 Fulgent Genetics, Inc. Business Overview
7.8.3 Fulgent Genetics, Inc. Next-Generation Gynecological Cancer Diagnostics Major Product Offerings
7.8.4 Fulgent Genetics, Inc. Next-Generation Gynecological Cancer Diagnostics Revenue in Global Market (2018-2023)
7.8.5 Fulgent Genetics, Inc. Key News
7.9 Illumina, Inc.
7.9.1 Illumina, Inc. Corporate Summary
7.9.2 Illumina, Inc. Business Overview
7.9.3 Illumina, Inc. Next-Generation Gynecological Cancer Diagnostics Major Product Offerings
7.9.4 Illumina, Inc. Next-Generation Gynecological Cancer Diagnostics Revenue in Global Market (2018-2023)
7.9.5 Illumina, Inc. Key News
7.10 F. Hoffmann-La Roche Ltd
7.10.1 F. Hoffmann-La Roche Ltd Corporate Summary
7.10.2 F. Hoffmann-La Roche Ltd Business Overview
7.10.3 F. Hoffmann-La Roche Ltd Next-Generation Gynecological Cancer Diagnostics Major Product Offerings
7.10.4 F. Hoffmann-La Roche Ltd Next-Generation Gynecological Cancer Diagnostics Revenue in Global Market (2018-2023)
7.10.5 F. Hoffmann-La Roche Ltd Key News
7.11 Laboratory Corporation of America Holdings
7.11.1 Laboratory Corporation of America Holdings Corporate Summary
7.11.2 Laboratory Corporation of America Holdings Business Overview
7.11.3 Laboratory Corporation of America Holdings Next-Generation Gynecological Cancer Diagnostics Major Product Offerings
7.11.4 Laboratory Corporation of America Holdings Next-Generation Gynecological Cancer Diagnostics Revenue in Global Market (2018-2023)
7.11.5 Laboratory Corporation of America Holdings Key News
7.12 ARUP Laboratories
7.12.1 ARUP Laboratories Corporate Summary
7.12.2 ARUP Laboratories Business Overview
7.12.3 ARUP Laboratories Next-Generation Gynecological Cancer Diagnostics Major Product Offerings
7.12.4 ARUP Laboratories Next-Generation Gynecological Cancer Diagnostics Revenue in Global Market (2018-2023)
7.12.5 ARUP Laboratories Key News
7.13 Myriad Genetics, Inc.
7.13.1 Myriad Genetics, Inc. Corporate Summary
7.13.2 Myriad Genetics, Inc. Business Overview
7.13.3 Myriad Genetics, Inc. Next-Generation Gynecological Cancer Diagnostics Major Product Offerings
7.13.4 Myriad Genetics, Inc. Next-Generation Gynecological Cancer Diagnostics Revenue in Global Market (2018-2023)
7.13.5 Myriad Genetics, Inc. Key News
7.14 OPKO Health, Inc.
7.14.1 OPKO Health, Inc. Corporate Summary
7.14.2 OPKO Health, Inc. Business Overview
7.14.3 OPKO Health, Inc. Next-Generation Gynecological Cancer Diagnostics Major Product Offerings
7.14.4 OPKO Health, Inc. Next-Generation Gynecological Cancer Diagnostics Revenue in Global Market (2018-2023)
7.14.5 OPKO Health, Inc. Key News
7.15 QIAGEN N.V.
7.15.1 QIAGEN N.V. Corporate Summary
7.15.2 QIAGEN N.V. Business Overview
7.15.3 QIAGEN N.V. Next-Generation Gynecological Cancer Diagnostics Major Product Offerings
7.15.4 QIAGEN N.V. Next-Generation Gynecological Cancer Diagnostics Revenue in Global Market (2018-2023)
7.15.5 QIAGEN N.V. Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Next-Generation Gynecological Cancer Diagnostics Market Opportunities & Trends in Global Market
Table 2. Next-Generation Gynecological Cancer Diagnostics Market Drivers in Global Market
Table 3. Next-Generation Gynecological Cancer Diagnostics Market Restraints in Global Market
Table 4. Key Players of Next-Generation Gynecological Cancer Diagnostics in Global Market
Table 5. Top Next-Generation Gynecological Cancer Diagnostics Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Next-Generation Gynecological Cancer Diagnostics Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Next-Generation Gynecological Cancer Diagnostics Revenue Share by Companies, 2018-2023
Table 8. Global Companies Next-Generation Gynecological Cancer Diagnostics Product Type
Table 9. List of Global Tier 1 Next-Generation Gynecological Cancer Diagnostics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Next-Generation Gynecological Cancer Diagnostics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Next-Generation Gynecological Cancer Diagnostics Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Next-Generation Gynecological Cancer Diagnostics Revenue in Global (US$, Mn), 2023-2030
Table 14. By Application ? Global Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - Next-Generation Gynecological Cancer Diagnostics Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Next-Generation Gynecological Cancer Diagnostics Revenue in Global (US$, Mn), 2023-2030
Table 17. By Region ? Global Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global Next-Generation Gynecological Cancer Diagnostics Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Next-Generation Gynecological Cancer Diagnostics Revenue (US$, Mn), 2023-2030
Table 20. By Country - North America Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2023-2030
Table 22. By Country - Europe Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2023-2030
Table 24. By Region - Asia Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2023-2030
Table 26. By Country - South America Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2023-2030
Table 28. By Country - Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2023-2030
Table 30. Quest Diagnostics Incorporated Corporate Summary
Table 31. Quest Diagnostics Incorporated Next-Generation Gynecological Cancer Diagnostics Product Offerings
Table 32. Quest Diagnostics Incorporated Next-Generation Gynecological Cancer Diagnostics Revenue (US$, Mn), (2018-2023)
Table 33. Thermo Fisher Scientific Inc. Corporate Summary
Table 34. Thermo Fisher Scientific Inc. Next-Generation Gynecological Cancer Diagnostics Product Offerings
Table 35. Thermo Fisher Scientific Inc. Next-Generation Gynecological Cancer Diagnostics Revenue (US$, Mn), (2018-2023)
Table 36. Agilent Technologies, Inc. Corporate Summary
Table 37. Agilent Technologies, Inc. Next-Generation Gynecological Cancer Diagnostics Product Offerings
Table 38. Agilent Technologies, Inc. Next-Generation Gynecological Cancer Diagnostics Revenue (US$, Mn), (2018-2023)
Table 39. Invitae Corporation Corporate Summary
Table 40. Invitae Corporation Next-Generation Gynecological Cancer Diagnostics Product Offerings
Table 41. Invitae Corporation Next-Generation Gynecological Cancer Diagnostics Revenue (US$, Mn), (2018-2023)
Table 42. Konica Minolta, Inc. Corporate Summary
Table 43. Konica Minolta, Inc. Next-Generation Gynecological Cancer Diagnostics Product Offerings
Table 44. Konica Minolta, Inc. Next-Generation Gynecological Cancer Diagnostics Revenue (US$, Mn), (2018-2023)
Table 45. BGI Genomics Corporate Summary
Table 46. BGI Genomics Next-Generation Gynecological Cancer Diagnostics Product Offerings
Table 47. BGI Genomics Next-Generation Gynecological Cancer Diagnostics Revenue (US$, Mn), (2018-2023)
Table 48. CENTOGENE N.V. Corporate Summary
Table 49. CENTOGENE N.V. Next-Generation Gynecological Cancer Diagnostics Product Offerings
Table 50. CENTOGENE N.V. Next-Generation Gynecological Cancer Diagnostics Revenue (US$, Mn), (2018-2023)
Table 51. Fulgent Genetics, Inc. Corporate Summary
Table 52. Fulgent Genetics, Inc. Next-Generation Gynecological Cancer Diagnostics Product Offerings
Table 53. Fulgent Genetics, Inc. Next-Generation Gynecological Cancer Diagnostics Revenue (US$, Mn), (2018-2023)
Table 54. Illumina, Inc. Corporate Summary
Table 55. Illumina, Inc. Next-Generation Gynecological Cancer Diagnostics Product Offerings
Table 56. Illumina, Inc. Next-Generation Gynecological Cancer Diagnostics Revenue (US$, Mn), (2018-2023)
Table 57. F. Hoffmann-La Roche Ltd Corporate Summary
Table 58. F. Hoffmann-La Roche Ltd Next-Generation Gynecological Cancer Diagnostics Product Offerings
Table 59. F. Hoffmann-La Roche Ltd Next-Generation Gynecological Cancer Diagnostics Revenue (US$, Mn), (2018-2023)
Table 60. Laboratory Corporation of America Holdings Corporate Summary
Table 61. Laboratory Corporation of America Holdings Next-Generation Gynecological Cancer Diagnostics Product Offerings
Table 62. Laboratory Corporation of America Holdings Next-Generation Gynecological Cancer Diagnostics Revenue (US$, Mn), (2018-2023)
Table 63. ARUP Laboratories Corporate Summary
Table 64. ARUP Laboratories Next-Generation Gynecological Cancer Diagnostics Product Offerings
Table 65. ARUP Laboratories Next-Generation Gynecological Cancer Diagnostics Revenue (US$, Mn), (2018-2023)
Table 66. Myriad Genetics, Inc. Corporate Summary
Table 67. Myriad Genetics, Inc. Next-Generation Gynecological Cancer Diagnostics Product Offerings
Table 68. Myriad Genetics, Inc. Next-Generation Gynecological Cancer Diagnostics Revenue (US$, Mn), (2018-2023)
Table 69. OPKO Health, Inc. Corporate Summary
Table 70. OPKO Health, Inc. Next-Generation Gynecological Cancer Diagnostics Product Offerings
Table 71. OPKO Health, Inc. Next-Generation Gynecological Cancer Diagnostics Revenue (US$, Mn), (2018-2023)
Table 72. QIAGEN N.V. Corporate Summary
Table 73. QIAGEN N.V. Next-Generation Gynecological Cancer Diagnostics Product Offerings
Table 74. QIAGEN N.V. Next-Generation Gynecological Cancer Diagnostics Revenue (US$, Mn), (2018-2023)
List of Figures
Figure 1. Next-Generation Gynecological Cancer Diagnostics Segment by Type in 2022
Figure 2. Next-Generation Gynecological Cancer Diagnostics Segment by Application in 2022
Figure 3. Global Next-Generation Gynecological Cancer Diagnostics Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Next-Generation Gynecological Cancer Diagnostics Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Next-Generation Gynecological Cancer Diagnostics Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Next-Generation Gynecological Cancer Diagnostics Revenue in 2022
Figure 8. By Type - Global Next-Generation Gynecological Cancer Diagnostics Revenue Market Share, 2018-2030
Figure 9. By Application - Global Next-Generation Gynecological Cancer Diagnostics Revenue Market Share, 2018-2030
Figure 10. By Region - Global Next-Generation Gynecological Cancer Diagnostics Revenue Market Share, 2018-2030
Figure 11. By Country - North America Next-Generation Gynecological Cancer Diagnostics Revenue Market Share, 2018-2030
Figure 12. US Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 13. Canada Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 14. Mexico Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 15. By Country - Europe Next-Generation Gynecological Cancer Diagnostics Revenue Market Share, 2018-2030
Figure 16. Germany Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 17. France Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 18. U.K. Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 19. Italy Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 20. Russia Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 21. Nordic Countries Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 22. Benelux Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 23. By Region - Asia Next-Generation Gynecological Cancer Diagnostics Revenue Market Share, 2018-2030
Figure 24. China Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 25. Japan Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 26. South Korea Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 27. Southeast Asia Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 28. India Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 29. By Country - South America Next-Generation Gynecological Cancer Diagnostics Revenue Market Share, 2018-2030
Figure 30. Brazil Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 31. Argentina Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 32. By Country - Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Revenue Market Share, 2018-2030
Figure 33. Turkey Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 34. Israel Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 35. Saudi Arabia Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 36. UAE Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 37. Quest Diagnostics Incorporated Next-Generation Gynecological Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 38. Thermo Fisher Scientific Inc. Next-Generation Gynecological Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 39. Agilent Technologies, Inc. Next-Generation Gynecological Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 40. Invitae Corporation Next-Generation Gynecological Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 41. Konica Minolta, Inc. Next-Generation Gynecological Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. BGI Genomics Next-Generation Gynecological Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. CENTOGENE N.V. Next-Generation Gynecological Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Fulgent Genetics, Inc. Next-Generation Gynecological Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Illumina, Inc. Next-Generation Gynecological Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. F. Hoffmann-La Roche Ltd Next-Generation Gynecological Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Laboratory Corporation of America Holdings Next-Generation Gynecological Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. ARUP Laboratories Next-Generation Gynecological Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Myriad Genetics, Inc. Next-Generation Gynecological Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. OPKO Health, Inc. Next-Generation Gynecological Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. QIAGEN N.V. Next-Generation Gynecological Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
